Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

Akif Kavgacı

doi:10.5606/tgkdc.dergisi.2023.23748

Akif Kavgacı¹, Serdar Kula¹, Fatma İncedere¹, Semiha Terlemez¹, Fatma Sedef Tunaoğlu¹

¹Department of Pediatrics, Division of Pediatric Cardiology, Gazi University Faculty of Medicine, Ankara, Türkiye

DOI : 10.5606/tgkdc.dergisi.2023.23748

Abstract
Turkish Abstract
Full Text
Full Text PDF
Similar Articles
E-mail to Author
How to Cite

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.

Keywords : Pulmonary arterial hypertension, subcutaneous, treprostinil

Viewed : 1165

Downloaded : 323